$9.1 Billion Mesenchymal Stem Cell Market by 2031 to be Focused on by New Senior Scientific Advisor for KALA BIO, Inc. (Nasdaq: KALA)

Image: https://www.globalnewslines.com/uploads/2026/04/1776342906.jpg

$KALA AI Platforms Enable Biotechs to Leverage Institutional-Grade AI Without Surrendering Control of Key Intellectual Property

* Clinical-Stage Biopharmaceutical Company Building a Dedicated, On-Premises AI Infrastructure Platform for the Biotechnology Industry.

* Initiative to be a Dedicated AI Infrastructure Partner for the Biotech Industry with On-Premises AI Systems Where Proprietary Data Never Leaves Client Control.

* Platform-as-a-Service Model to Generate Recurring Revenue by Licensing AI Capabilities Where Top 20 Pharma Companies Invested $167 Billion in 2024.

* KALA to Serve as First Deployment Client, Applying Researgency to its Proprietary MSC-S Biological Datasets and KPI-012 Clinical Program.

* Exclusive Worldwide License on Researgency Platform for 12-Month Term with Renewal Options; Platform Architecture designed for Multi-Client Deployment.

* New Senior Scientific Advisor to Assess Clinical Assets, Development Options, and AI-Enabled Analytical Opportunities Including MSC Secretome Platform.

* Bionic Intelligence Research Agent Now Live for Secure, Scalable, Autonomous Research Solutions to Global Biotechnology and Pharmaceutical Organizations.

* Red Light Holland Engages KALA Researgency.AI Platform to Support Clinical Development of Filament's Patented PEX010 Botanical Psilocybin Drug Candidate

* Launch of First AI Agent Deploying as $180 Billion Agentic AI Healthcare Revolution Accelerates.

* Data-Sovereign Architecture to Differentiate Researgency from Centralized AI Platforms will Enable Biotechs to Leverage Institutional-Grade AI Without Surrendering Control of Intellectual Property.

KALA BIO, Inc. (Nasdaq: KALA) is a clinical-stage biopharmaceutical company building a dedicated, on-premises AI infrastructure platform for the biotechnology industry. The KALA dual strategy combines a proprietary biologics pipeline, including its mesenchymal stem cell secretome (MSC-S) platform and FDA Orphan Drug and Fast Track designated product candidates, with a scalable AI platform-as-a-service business designed to deploy secure, purpose-built AI systems directly within biotech and pharmaceutical client environments.

Through its exclusive license for the Researgency AI research platform, KALA intends to serve as the dedicated AI infrastructure partner for the biotechnology industry, enabling companies of all sizes to unlock the value of their proprietary biological data without ever surrendering control of it.

Image: https://www.globalnewslines.com/uploads/2026/04/bd7ac2657e658a8dbdbc0942a2a24b08.jpg

KALA Engages Dr. Saeid Babaei as Senior Scientific Advisor to Evaluate Clinical Assets and Precision Development Opportunities

On April 1st KALA announced the engagement of Dr. Saeid Babaei, PhD, MBA, as Senior Scientific Advisor. Dr. Babaei will focus on advising on the evaluation of KALA clinical and molecular assets, including the proprietary MSC Secretome platform, through the potential application of AI-enabled analytics, digital health tools, and secure data integration approaches. His mandate includes advising on clinical development considerations, assessing hypotheses related to potential responder subgroups, and contributing scientific input to the development of a responsible, regulatory-conscious analytical framework for enterprise-scale biotech applications.

This collaboration marks a pivotal step in the KALA strategy to maximize the commercial and scientific value of its existing clinical assets through innovation and precision analytics. The initial phase will include a review of historical datasets, trial protocols, and translational hypotheses to help inform strategic considerations for future development and potential partnering, licensing, or commercialization pathways.

A focus of this engagement is evaluating the KALA work in the MSC secretome space. The secretome, the collection of bioactive molecules and extracellular vesicles secreted by mesenchymal stem cells, represents one of the most rapidly advancing frontiers in regenerative biologics and cell and gene therapies.

Analysts project the mesenchymal stem cell market to grow from approximately USD 5.1 billion in 2026 to USD 9.1 billion by 2031, reflecting a compound annual growth rate exceeding 12%. Secretome-derived therapies and extracellular vesicle platforms represent a significant component of that expansion.

Dr. Babaei will help evaluate the scientific and potential commercial relevance of the KALA secretome platform and consider possible pathways for future development, partnering, licensing, or strategic collaboration.

Industry-Leading AI Infrastructure: Bionic Intelligence Research Agent Now

LiveOn March 30th KALA announced the initial commercial deployment of the Bionic Intelligence Research Agent (BIRA), the Company's first purpose-built agentic AI solution delivered through its Researgency.ai platform (under exclusive worldwide license with Younet)

The launch follows the KALA March 11 announcement that its first AI agent would ship within 14 days, a commitment Kala has met on schedule, demonstrating KALA ability to execute on commitments and its readiness to deliver commercial-grade AI solutions at enterprise scale.

The KALA Bionic Intelligence Research Agent is a fully autonomous AI research specialist built for the biotechnology and pharmaceutical sectors. Powered by Researgent 2.0, a 70-billion-parameter large language model trained on vast datasets in the biotech, healthcare, and scientific research sectors, BIRA delivers next-generation performance within secure enterprise infrastructure.

Image: https://www.globalnewslines.com/uploads/2026/04/88094d401fc4f2b96ec5a97c2d2fe0ac.jpg

Unlike public AI platforms, KALA BIRA operates solely within client-controlled, VPN-secured environments, guaranteeing full data sovereignty with no external access to proprietary research data; enterprise-grade security that complies with pharmaceutical R&D standards; complete audit trails for regulatory documentation; and real-time performance with minimal cloud latency.

The KALA BIRA architecture integrates smoothly with Younet's Researgency platform infrastructure, designed to scale with the complexity of client organisations, leverage existing enterprise infrastructure investments, support a platform-as-a-service model for recurring revenue, and enable swift deployment across multiple business units. This scalable approach ensures that organizations of any size can benefit from the platform's AI solutions without sacrificing security or performance.

With thousands of biotech and pharma companies worldwide facing research bottlenecks, compliance challenges, and competitive intelligence issues, KALA BIRA is positioned to tap into a significant market opportunity. The target market includes the global biotechnology and pharmaceutical sectors. The platform's main differentiation is its on-premises secure deployment model compared to public cloud AI options. The KALA BIRA core value proposition focuses on proprietary data control combined with enterprise-scale AI performance, while the revenue model is based on platform-as-a-service with scalable recurring income potential.

Red Light Holland Engages KALA Researgency.AI Platform to Support Clinical Development of Filament's Patented PEX010 Botanical Psilocybin Drug Candidate

On March 18th Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) and KALA announced that Red Light has engaged KALA with its Researgency.ai agentic artificial intelligence platform under world wide license from Younet to support the clinical development strategy for PEX010, the patented botanical psilocybin drug candidate originated by Filament Health Corp. The engagement will deploy the KALA purpose-built AI research agents to assist in clinical planning, protocol optimization and scenario modeling as Red Light advances PEX010 through its regulated drug development program.

Strategic Initiative to Deploy and Continue to Develop an On-Premises AI Infrastructure Platform for the Biotech Industry

On March 4thKALA announced a strategic initiative to build a biotechnology industry dedicated, on-premises artificial intelligence infrastructure platform, designed to be deployed directly within biotech and pharmaceutical client environments, enabling companies across the life sciences sector to unlock additional potential of their proprietary biological data without ever surrendering control of it.

KALA also announced that it has entered into a Platform Development and Exclusive License Agreement with 2624465 Ontario Inc., operating as Younet AI, for a proprietary AI research platform, internally designated "Researgency," designed to deploy custom, secure, large language models ("LLMs") purpose-built for biomedical research and data science applications. The Agreement provides KALA with initial platform access during a 12-month initial term and the option, in the sole discretion of KALA, to extend the Agreement for successive 12-month renewal terms.

The biotechnology industry faces a fundamental structural problem: thousands of small and mid-cap biotech companies are generating enormous volumes of proprietary biological data, from preclinical studies, clinical trials, genomic sequencing, protein interaction mapping, and secretome analysis, but the vast majority of these companies lack the internal resources, infrastructure, or specialized talent to deploy advanced AI capabilities against that data. At the same time, these companies are rightly unwilling to surrender their most sensitive intellectual property, the biological data, trade secrets, and clinical datasets that represent years of investment and form the core of their competitive advantage, to centralized, third-party cloud platforms.

KALA intends to solve this problem. The KALA vision is to serve as a dedicated AI infrastructure partner for the biotechnology industry, deploying the Researgency platform directly within each client's own secure environment, on their own servers, under their own control. In this model, KALA would provide the AI platform, the purpose-built biomedical agents, and the ongoing optimization, while the client would retain full ownership and custody of their data at all times. No proprietary information would ever leave the client's infrastructure. No biological data would be shared with public AI services.

KALA believes this on-premises, data-sovereign approach represents a fundamentally different model from the centralized AI platforms currently operating in the life sciences space. While established AI drug discovery companies, including well-funded, publicly traded platforms with billion-dollar market capitalizations, typically require clients to upload proprietary data to centralized cloud environments, the KALA architecture is designed from inception to go to the client, not the other way around. This distinction is critical in an industry where intellectual property, trade secrets, and regulatory-sensitive data represent the most valuable assets a company possesses.

The Market Opportunity: $167+ Billion R&D Ecosystem Underserved by AI

The global AI drug discovery market is projected to grow at a compound annual growth rate approximately 25%,1 driven by AI's demonstrated ability to compress traditional drug development timelines, which historically average 10 to 15 years and cost up to $2.6 billion per approved drug,2 to potentially as little as 12 to 18 months for preclinical candidate nomination, while reducing costs by an estimated 30 to 40 percent.3 Dozens of AI-designed drug candidates are currently in clinical trials globally, up from only three in 2016,4 with the first AI-discovered drug approvals anticipated in the near term.

Image: https://www.globalnewslines.com/uploads/2026/04/e3935b8339db3feb0e568ddf258a5f60.jpg

The world's twenty largest pharmaceutical companies collectively invested approximately $167 billion in research and development in 2024,5 yet the pharmaceutical industry's combined investment in AI-driven drug discovery was estimated at approximately $4 billion in 2025, expected to grow to approximately $25 billion by 2030.6 KALA believes this represents one of the largest technology adoption gaps in any major industry.

More importantly, KALA believes the addressable market for on-premises, secure, purpose-built AI infrastructure, specifically designed for small and mid-cap biotech companies that cannot afford to build in-house AI capabilities and are unwilling to send proprietary data to centralized platforms, is substantially underserved. There are over 3,200 biotechnology companies in the United States alone,7 the majority of which are generating biological data that could benefit from AI-driven analysis but lack a viable, secure path to deploying it. KALA believes this segment represents a significant near-term revenue opportunity for a platform specifically architected to serve their needs.

For more information on KALA visit www.kalarx.com [http://www.kalarx.com/]

Email: AM@kalarx.com [https://www.globenewswire.com/Tracker?data=20tODq6ntwKAW5ipediDTaEfvGeLw6GFbPI4SnQArZH59Hbpxr3P7Tx0tXZsedUbfB4NCojUUN69fK-bSQZ6Bg==]

DISCLAIMER: https://corporateads.com/disclaimer/

Disclosure listed on the CorporateAds website
Media Contact
Company Name: KALA BIO, Inc. (Nasdaq: KALA)
Contact Person: Avi Minkowitz, CEO
Email: Send Email [http://www.universalpressrelease.com/?pr=91-billion-mesenchymal-stem-cell-market-by-2031-to-be-focused-on-by-new-senior-scientific-advisor-for-kala-bio-inc-nasdaq-kala]
Phone: (781) 996-5252
Address:1167 Massachusetts Avenue
City: Arlington
State: MA 02476
Country: United States
Website: http://www.kalarx.com

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. GetNews makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.